Seeking Alpha
29 Oct 2026, 07:40 UTC · 1h ago
Johnson & Johnson: Strong Q3 Growth, But 2027 Could Test Its Earnings
Impact · against what's priced in
The Q3 results are largely noise as the raised 2026 guidance and Tremfya's growth are already baked into the current valuation. While Innovative Medicine remains strong, continued weakness in MedTech segments like Surgery and Abiomed reinforces the market's skepticism regarding the company's ability to accelerate overall growth toward the 13.1% required for a higher multiple.
- JNJ+0.05
Already priced in
- The price assumes
raised 2026 revenue guidance of $100.3–$101.3 billion and adjusted EPS of $11.45–$11.65
The reported raise in 2026 guidance and adjusted EPS confirms the trajectory the market has already integrated into the current price.
What JNJ's price assumes · Sep 3
